Robert Canada, MD
Nephrology · Memphis, TNNPI 1033176250
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by AstraZeneca at 48.6% of the total. Reporting peaked in 2019 at $7,261 and has fallen 50.5% since, to $3,592 in 2025. Among nephrology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $50.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Bayer$1K
- Vantive US Healthcare LLC$929
- Gilead$763
- Fresenius USA Marketing, Inc.$759
- Nxstage Medical, Inc.$756
- plus $6K from 30 others
What the payments were for
- Speaking & faculty fees$7,25036%
- Travel & lodging$1,4557%
- Food & beverage$10,94954%
- Education$5443%
- Other$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 74 | $9,834 |
| Bayer | 43 | $1,056 |
| Vantive US Healthcare LLC | 9 | $929 |
| Gilead | 12 | $763 |
| Fresenius USA Marketing, Inc. | 36 | $759 |
| Nxstage Medical, Inc. | 8 | $756 |
| Otsuka America Pharmaceutical, Inc. | 24 | $720 |
| Aurinia Pharma U.S., Inc. | 25 | $687 |
| Travere Therapeutics, Inc. | 31 | $662 |
| Mallinckrodt Hospital Products Inc. | 18 | $645 |
| Ardelyx, Inc. | 14 | $483 |
| Amgen | 16 | $413 |
| Sanofi | 3 | $266 |
| Viiv Healthcare Company | 4 | $266 |
| ANI Pharmaceuticals, Inc. | 13 | $246 |
| Akebia Therapeutics Inc | 5 | $202 |
| Vifor Pharma, Inc. | 11 | $197 |
| GSK | 10 | $191 |
| Janssen Products, LP | 2 | $154 |
| Novartis | 6 | $153 |
| Bard Peripheral Vascular, Inc. | 1 | $148 |
| Mallinckrodt Enterprises LLC | 4 | $146 |
| OPKO Pharmaceuticals, LLC | 5 | $84 |
| Calliditas Therapeutics US Inc. | 3 | $71 |
| Theratechnologies Inc. | 4 | $67 |
| AbbVie | 4 | $55 |
| Pfizer | 2 | $43 |
| Cormedix Inc. | 2 | $42 |
| Vyera Pharmaceuticals, LLC | 2 | $35 |
| Cook Medical LLC | 2 | $32 |
| Johnson & Johnson | 2 | $27 |
| Welch Allyn | 1 | $27 |
| Lilly USA, LLC | 1 | $27 |
| Boehringer Ingelheim | 1 | $19 |
| Merck | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$8,530
- Renal - Acute$703
- NXSTAGE SYSTEM ONE$387
- Kerendia$261
- LIBERTY SELECT CYCLER$252
- TERLIVAZ$150
- Filspari$125
- AURYXIA$123
- Vafseo$123
- Velphoro$122
- Biktarvy$120
- CABENUVA$114
- WAYRILZ$114
- CABLIVI$114
- DOVATO$109
- LUPKYNIS$106
- Parsabiv$106
- Descovy$105
- XPHOZAH 30 MG$104
- FARXIGA$101
How this compares
$20,226 in reported general payments places this provider in the 90th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 43 | $103,441 |
| FarxigaDapagliflozin Propanediol | 80 | $96,114 |
| SamscaTolvaptan | 12 | $91,044 |
| XphozahTenapanor Hcl | 15 | $66,627 |
| JardianceEmpagliflozin | 27 | $32,385 |
| KerendiaFinerenone | 13 | $14,562 |
| Sevelamer Carbonate | 43 | $10,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,059 |
| ProsolParenteral Amino Acid 20% No.1 | 13 | $1,986 |
| Losartan Potassium | 85 | $979 |
| Cinacalcet Hcl | 11 | $946 |
| Hydralazine Hcl | 51 | $759 |
| Calcitriol | 32 | $744 |
| Amlodipine Besylate | 111 | $655 |
| ClopidogrelClopidogrel Bisulfate | 19 | $551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $759 | $103,44143 claims |
| AstraZenecaFarxiga | $9,834 | $96,11480 claims |
| Boehringer IngelheimJardiance | $19 | $32,38527 claims |
| BayerKerendia | $1,056 | $14,56213 claims |
| GSKAnoro Ellipta | $191 | $6,05912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Memphis
- Omar HamzeMemphis$90K
- Omar DavisMemphis$70K
- Natarsha GrantMemphis$53K
- Marc StegmanMemphis$41K
- Minesh PathakMemphis$14K
- Miklos MolnarMemphis$12K
- Wael HusseinMemphis$10K
- Sanjeev MittalMemphis$9K
- Vasanthi BalaramanMemphis$8K
- Mark Abi NaderMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.